Oruka Therapeutics (ORKA) Short-term Investments (2016 - 2026)

Oruka Therapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $339.3 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 27.79% year-over-year to $339.3 million in Q1 2026; TTM through Mar 2026 was $339.3 million, a 27.79% increase from a year earlier, with the FY2025 full-year figure at $290.1 million, down 7.63% from the prior year.
• Short-term Investments climbed to $339.3 million in Q1 2026 per ORKA's latest filing, from $290.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $339.3 million in Q1 2026 and bottomed at $257.9 million in Q3 2025.
• The 3-year median for Short-term Investments is $277.8 million (2025), against an average of $288.3 million.
• Across the five-year window, Short-term Investments retreated 7.63% in 2025 and gained 27.79% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $314.1 million in 2024, then dropped by 7.63% to $290.1 million in 2025, then climbed by 16.96% to $339.3 million in 2026.
• Per Business Quant, the three latest ORKA Short-term Investments figures stand at $339.3 million (Q1 2026), $290.1 million (Q4 2025), and $257.9 million (Q3 2025).